United Therapeutics Gets Dual Target Hikes From BofA and Wells Fargo [Yahoo! Finance]
United Therapeutics Corporation (UTHR)
Last united therapeutics corporation earnings: 4/29 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.unither.com/investor-relations
Company Research
Source: Yahoo! Finance
The results validate a meaningful expansion of Tyvaso's addressable market beyond pulmonary arterial hypertension into idiopathic pulmonary fibrosis, a condition with significant unmet need and limited treatment options. Ticker Company Firm Old Target New Target Rating One-Line Takeaway UTHR United Therapeutics BofA Neutral IPF monotherapy and adjunct role seen as credible; stock already above new target UTHR United Therapeutics Wells Fargo Equal Weight 95% probability of approval assigned; positive data described as "a nice win" The Analyst's Case BofA analyst Jason Gerberry raised his price target to $626 from $569, keeping a Neutral rating. Based on the combined TETON-1 and TETON-2 results, BofA sees a role for Tyvaso as both a monotherapy for patients unable to tolerate anti-fibrotics and as an adjunct therapy on top of anti-fibrotics. That dual-pathway argument is significant: it broadens the potential patient population rather than limiting
Show less
Read more
Impact Snapshot
Event Time:
UTHR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UTHR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UTHR alerts
High impacting United Therapeutics Corporation news events
Weekly update
A roundup of the hottest topics
UTHR
News
- United Therapeutics (UTHR) had its price target raised by HC Wainwright from $600.00 to $660.00. They now have a "buy" rating on the stock.MarketBeat
- United Therapeutics (UTHR) had its price target raised by Wells Fargo & Company from $486.00 to $575.00. They now have an "equal weight" rating on the stock.MarketBeat
- United Therapeutics (UTHR) had its price target raised by Bank of America Corporation from $569.00 to $626.00. They now have a "neutral" rating on the stock.MarketBeat
- Why United Therapeutics (UTHR) Stock Is Up Today [Yahoo! Finance]Yahoo! Finance
- United Therapeutics Stock Soars on Strong Phase 3 Lung Disease Results [Yahoo! Finance]Yahoo! Finance
UTHR
Earnings
- 10/29/25 - Beat
UTHR
Sec Filings
- 3/31/26 - Form 4
- 3/31/26 - Form 4
- 3/31/26 - Form 4
- UTHR's page on the SEC website